Cargando…
Engineering SARS-CoV-2 cocktail antibodies into a bispecific format improves neutralizing potency and breadth
One major limitation of neutralizing antibody-based COVID-19 therapy is the requirement of costly cocktails to reduce antibody resistance. We engineered two bispecific antibodies (bsAbs) using distinct designs and compared them with parental antibodies and their cocktail. Single molecules of both bs...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820655/ https://www.ncbi.nlm.nih.gov/pubmed/35132410 http://dx.doi.org/10.1101/2022.02.01.478504 |